The Europe preclinical Contract Research Organization (CRO) market size was estimated to be USD 1.8 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2030. This steady growth is primarily driven by the rising prevalence of chronic diseases, which creates a strong demand for novel and effective treatments. Additionally, increased research and development (R&D) expenditure by pharmaceutical and biotechnology companies fuels the need for specialized testing services, further propelling the market expansion in the region.

Moreover, the presence of leading pharmaceutical corporations generating substantial revenue, such as F. Hoffmann-La Roche Ltd and Novartis, strengthens Europe’s position within the preclinical CRO sector. These prominent companies often outsource their preclinical trial activities to local CROs to leverage specialized expertise and cost efficiencies. Small and mid-sized biotech firms are also increasingly outsourcing clinical trials, contributing to the overall market growth.

In 2023, Europe accounted for approximately 31.6% of the total global revenue share in the preclinical CRO market, highlighting its significant role on the world stage. The region’s growth outlook remains promising, supported by consistent R&D investments and the strategic outsourcing trend aimed at accelerating drug development timelines while controlling expenses.

Additionally, regulatory frameworks in Europe, particularly those overseen by the European Medicines Agency (EMA), play a critical role in shaping the market. The EMA’s guidelines and recommendations for the authorization of new and active medicines ensure rigorous standards for preclinical CRO services, which not only enhance the quality of drug development but also contribute to the growth and reliability of the market in Europe.

Key Market Trends & Insights:

• In 2023, the United Kingdom (UK) held a dominant position within the European preclinical Contract Research Organization (CRO) market, accounting for the largest market share of 25.0% across the region. This highlights the UK's strong influence and leadership in the preclinical CRO sector compared to other European countries.

• When examining the market by model type, patient-derived organoid (PDO) models emerged as the leading category in 2023, capturing the largest revenue share of 80.6%. This significant share underscores the growing importance and adoption of PDO models in preclinical research due to their ability to closely mimic human biology and disease conditions.

• In terms of end-use, biopharmaceutical companies dominated the market segment, holding a substantial revenue share of 80.1% in 2023. This dominance reflects the critical role that biopharmaceutical firms play in driving demand for preclinical CRO services as they seek efficient and specialized testing solutions to advance their drug development pipelines.

• By service type, the toxicology testing segment led the market in 2023, accounting for a revenue share of 26.1%. The prominence of toxicology testing emphasizes its essential role in assessing the safety profile of new drug candidates during the preclinical phase, ensuring that potential therapies meet regulatory standards before moving to clinical trials.

Order a free sample PDF of the Europe Preclinical CRO Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 5.12 Billion

• 2030 Projected Market Size: USD 6.58 Billion

• CAGR (2025-2030): 4.4%

Key Companies & Market Share Insights:

The key players operating in the market include prominent companies such as Eurofins Scientific, Atlant Clinical, ALS Food and Pharmaceutical, Davids Biotechnologie GmbH, among others. These organizations play a vital role in shaping the industry through their extensive services and capabilities.

Eurofins Scientific is a global leader with more than 900 laboratories spread across various countries. The company offers an extensive portfolio consisting of over 200,000 analytical methods. Their services primarily focus on testing for food, environmental samples, pharmaceuticals, and cosmetic products. Additionally, Eurofins provides specialized services in discovery pharmacology and agroscience, catering to a broad spectrum of industries.

Atlant Clinical delivers comprehensive clinical trial services covering all phases, from Phase I through Phase IV, along with essential support functions. Their operations extend throughout Europe, Russia, the Commonwealth of Independent States (CIS), and the Baltic States. The company boasts robust expertise in all key therapeutic areas and is well-equipped to manage and successfully execute even the most complex and demanding clinical trials, demonstrating their strong position in the market.

Key Players

• Eurofins Scientific

• Atlant Clinical

• ASSAY Clinical Research

• ALS Food and Pharmaceutical

• Comp5

• Davids Biotechnologie GmbH

• ABX-CRO advanced pharmaceutical services GmbH

• Charles River Laboratories International, Inc.

• ERBC Group.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The European preclinical Contract Research Organization (CRO) market is experiencing robust growth, driven by factors such as the increasing prevalence of chronic diseases, heightened R&D investments by pharmaceutical and biotechnology companies, and a growing demand for specialized testing services. The market's expansion is further supported by the presence of leading pharmaceutical corporations and the rising trend of outsourcing clinical trials by small and mid-sized biotech companies. However, challenges like the shortage of skilled professionals and variations in regulatory standards across countries may impact market growth.